CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 21 enrolled
Drug / intervention
ONEXTON Topical Geldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03402893
NCT03402893Phase 4Completed
CompareCT.gov

The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color

Derm Research, PLLC·interventional·Posted Jan 18, 2018·Updated Apr 2, 2019

In Brief

A Phase 4 clinical trial evaluating ONEXTON Topical Gel for Acne Vulgaris and Post Inflammatory Hyperpigmentation. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This is a single-center, open label pilot study. The study is comprised of 5 study visits; Screening, Baseline, and Weeks 4, 8, and 16. All subjects will receive Onexton at Baseline and be instructed to apply the gel once daily to the face. The investigators will evaluate Investigator Global Assessment of acne (IGA), total lesion count, inflammatory lesion count, non-inflammatory lesion count, Investigator Global Assessment of Post-Inflammatory Hyperpigmentation and distribution of Post-Inflammatory Hyperpigmentation, adverse events and concomitant medications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris, Post Inflammatory Hyperpigmentation
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedJan 18, 2018
Enrollment StartJul 28, 2017
Primary CompletionNov 15, 2017
Study CompletionFeb 28, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.5 years ago

Interventions

ONEXTON Topical Geldrug

Onexton gel applied once daily to face